The stock of AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) is now priced at $7.6 and the shares are 2.11 points up or 38.43% higher compared to its previous closing price of $5.49. The stock had 15.531 million contracts set over the past session. ANPC shares’ daily volume is compared to its average trading volume at 256129 shares. However, it has a float of 2.3 million and although its performance was 19.69% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the ANPC share price recently placing at $6.8 to $10.6.
The shorts are running away from the AnPac Bio-Medical Science Co., Ltd. stock, with the latest data on short interest released on July 15, 2020, showing that short interest numbers in the ANPC shares have declined. Short interest in the stock represents just 0.01% of its float, but the volume has dropped by -172. The volume of shorted shares dropped to 344 from 516 shares over the last two weeks. The average intraday trading volume has been 3100 shares, which means that days to cover moved to roughly 1.
Looking at current readings, AnPac Bio-Medical Science Co., Ltd.’s two-week RSI is 61.58. This suggests that the stock is neutral at the moment and that ANPC shares’ price movement remains stable. The stochastic readings are equally revealing at 23.94% meaning the ANPC share price is currently in overbought territory.
The technical chart shows that the ANPC stock will likely settle at between $9.87 and $12.13 per share. However, if the stock dips below $6.07, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $4.53.
Currently, the stock is trading in the green of MACD, with a reading of 0.04. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
The average rating for the ANPC equity is 2 and is currently gathering a bullish momentum. Of 1 analysts tracking AnPac Bio-Medical Science Co., Ltd. polled by Reuters, 0 rated ANPC as a hold. The remaining 1 analysts were split evenly. However, the split wasn’t equal as a majority (1) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.